Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis

Completed · Phase 3

Conditions studied: Cirrhosis

In brief

The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled. The study hypothesis is that measurement of the MBT will allow earlier detection of a decline in liver function in patients with cirrhosis who are awaiting liver transplantation.

Key facts

Study ID
NCT01157845
Run by
Virginia Commonwealth University
People needed
165
Starts
2010-03-01
Expected to finish
2012-07-01
Last updated by the study team
2014-05-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.